Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
4
×
biotech
boston blog main
boston top stories
4
×
europe blog main
europe top stories
4
×
life sciences
national blog main
national top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
eli lilly
fda
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
allergan
alzheimer's disease
biofourmis
boehringer ingelheim
cancer
chronic kidney disease
covid-19
What
bio
roundup
debut
drug
moves
week
abbvie’s
acquisitions
ahead
alkermes
antipsychotic
benefits
biggest
biofourmis
black
bucks
build
buy
cancer
caveats
celebrate
ceo
chance
commonly
companies
company’s
continue
corner
daniel
day
days
designed
diamond
diamond’s
dyne’s
effect
favor
fda
forward
gain
Language
unset
4
×
Current search:
abbvie
×
unset
×
" boston top stories "
×
" europe top stories "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More